Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Presentation and management of gastrointestinal stromal tumours.

Mongan AM, Malik V, Rowley S, Claxton Z, Muldoon C, O'Toole D, Ravi N, Reynolds JV.

Ir Med J. 2013 Jun;106(6):176-9.

PMID:
23909154
2.

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.

DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology.

Ann Surg. 2013 Sep;258(3):422-9. doi: 10.1097/SLA.0b013e3182a15eb7.

3.

Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.

Majer IM, Gelderblom H, van den Hout WB, Gray E, Verheggen BG.

J Med Econ. 2013 Sep;16(9):1106-19. doi: 10.3111/13696998.2013.819357. Epub 2013 Jul 19.

PMID:
23808902
4.

Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era?

Cananzi FC, Lorenzi B, Belgaumkar A, Benson C, Judson I, Mudan S.

Langenbecks Arch Surg. 2014 Mar;399(3):323-32. doi: 10.1007/s00423-014-1160-3. Epub 2014 Jan 12.

PMID:
24413830
5.

Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.

Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, Liang XB, Cao H, Yan ZS, Shi YQ.

Eur J Cancer. 2014 Jul;50(10):1772-8. doi: 10.1016/j.ejca.2014.03.280. Epub 2014 Apr 22.

PMID:
24768330
6.

Gastrointestinal stromal tumors: diagnosis and treatment.

Acín-Gándara D, Pereira-Pérez F, Castaño-Pascual A, Durán-Poveda M, Antequera-Pérez A, Miliani-Molina C.

Cir Cir. 2012 Jan-Feb;80(1):44-51.

PMID:
22472152
7.

Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.

Saito S, Nakata K, Kajiura S, Ando T, Hosokawa A, Sugiyama T.

Digestion. 2013;87(1):47-52. doi: 10.1159/000343938. Epub 2013 Jan 21.

PMID:
23343969
8.

[New prospective on adjuvant treatment for gastrointestinal stromal tumors].

Pan ZZ, Wu XJ.

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Mar;16(3):212-5. Chinese.

PMID:
23536337
9.

Surgical management of gastrointestinal stromal tumours: a single centre experience during the past 17 years.

De Vogelaere K, Van De Winkel N, Aerts M, Haentjens P, Spitali C, Van Loo I, Delvaux G.

Acta Chir Belg. 2014 May-Jun;114(3):167-73.

PMID:
25102705
10.
11.

Clinicopathological study of 113 gastrointestinal stromal tumors.

Bhalgami R, Manish K, Patil P, Mehta S, Mohandas KM.

Indian J Gastroenterol. 2013 Jan;32(1):22-7. doi: 10.1007/s12664-012-0273-2. Epub 2012 Dec 8.

PMID:
23224791
12.

Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.

Tielen R, Verhoef C, van Coevorden F, Gelderblom H, Sleijfer S, Hartgrink HH, Bonenkamp JJ, van der Graaf WT, de Wilt JH.

Eur J Surg Oncol. 2013 Feb;39(2):150-5. doi: 10.1016/j.ejso.2012.09.004. Epub 2012 Oct 16.

13.

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.

Shen C, Chen H, Yin Y, Chen J, Zhang B, Chen Z, Chen J.

Clinics (Sao Paulo). 2014 Nov;69(11):758-62. doi: 10.6061/clinics/2014(11)09.

14.

Updates on the management of gastrointestinal stromal tumors.

Bamboat ZM, Dematteo RP.

Surg Oncol Clin N Am. 2012 Apr;21(2):301-16. doi: 10.1016/j.soc.2011.12.004.

15.

Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.

Pandey R, Kochar R.

J Gastrointest Cancer. 2012 Dec;43(4):547-52. doi: 10.1007/s12029-012-9423-0. Review.

PMID:
22847491
16.

Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.

Jakob J, Mussi C, Ronellenfitsch U, Wardelmann E, Negri T, Gronchi A, Hohenberger P.

Ann Surg Oncol. 2013 Feb;20(2):586-92. doi: 10.1245/s10434-012-2647-1. Epub 2012 Sep 11.

PMID:
22965573
17.

Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection.

Tirumani SH, Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH, Raut CP.

Eur J Surg Oncol. 2014 Apr;40(4):420-8. doi: 10.1016/j.ejso.2013.10.021. Epub 2013 Nov 5.

PMID:
24238762
18.

Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.

Kang YK, Kang BW, Im SA, Lee JL, Park SR, Kang WK, Chang HM, Kim TW, Oh DY, Jung KH, Ryu MH.

Cancer Chemother Pharmacol. 2013 Jan;71(1):43-51. doi: 10.1007/s00280-012-1970-3. Epub 2012 Oct 7. Erratum in: Cancer Chemother Pharmacol. 2013 Feb;71(2):551-2.

PMID:
23053257
19.

NCCN Task Force report: gastrointestinal stromal tumor (GIST).

Demetri G, DeMatteo RP.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 3:S-25-8. No abstract available.

PMID:
23570095
20.

A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.

Ogata K, Mochiki E, Ojima H, Haga N, Fukuchi M, Aihara R, Ando H, Uchida N, Toyomasu Y, Suzuki M, Kimura A, Kogure N, Yokobori T, Ohno T, Kuwano H.

J Surg Oncol. 2014 Dec;110(8):942-6. doi: 10.1002/jso.23773. Epub 2014 Aug 28.

PMID:
25164620
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk